1. Home
  2. ZURA vs CLB Comparison

ZURA vs CLB Comparison

Compare ZURA & CLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$0.97

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

N/A

Current Price

$7.80

Market Cap

414.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ZURA
CLB
Founded
2022
1936
Country
United States
United States
Employees
N/A
3300
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
414.2M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
ZURA
CLB
Price
$0.97
$7.80
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$8.00
★ $15.00
AVG Volume (30 Days)
★ 6.7M
644.2K
Earning Date
10-27-2026
10-28-2026
Dividend Yield
N/A
★ 0.48%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 0.23
Revenue
N/A
★ $526,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.52
P/E Ratio
★ N/A
$36.57
Revenue Growth
N/A
★ 0.51
52 Week Low
$0.92
$8.12
52 Week High
$7.25
$20.36

Technical Indicators

Market Signals
Indicator
ZURA
CLB
Relative Strength Index (RSI) 24.64 24.32
Support Level $0.93 N/A
Resistance Level $5.97 $10.76
Average True Range (ATR) 0.23 0.42
MACD -0.15 -0.10
Stochastic Oscillator 0.46 3.59

Price Performance

Historical Comparison
ZURA
CLB

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About CLB Core Laboratories Inc.

Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.

Share on Social Networks: